Ocoxin oral solution demonstrates antiviral properties in cellular models

Pandiella,Atanasio; Sanz,Eduardo; Díaz‑Rodríguez,Elena

doi:10.3892/etm.2021.10561

Ocoxin oral solution demonstrates antiviral properties in cellular models

Authors:
- Atanasio Pandiella
- Eduardo Sanz
- Elena Díaz‑Rodríguez
View Affiliations

Affiliations: Institute of Molecular and Cellular Cancer Biology, Cancer Research Institute of Salamanca, Spanish Research Council‑Institute for Biomedical Research of Salamanca, 37007 Salamanca, Spain, Catalysis S.L., 28016 Madrid, Spain
Published online on: August 5, 2021 https://doi.org/10.3892/etm.2021.10561
Article Number: 1127
Copyright: © Pandiella et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ocoxin Oral Solution (OOS) and Viusid (VS) are nutritional supplements that include several natural products which affect different cellular functions, such as proliferation or the redox status. In addition, some of their constituent components have been described to exert an antiviral effect. Considering this, it was hypothesized that treatment with OOS and VS could protect from viral infections. In order to evaluate the impact of OOS and VS on viral infection, lentivirus and retrovirus whose genomes coded for green fluorescent protein were used. In addition, and as a second approach to measure viral infection, a hemagglutinin‑tagged form of the mitogen‑activated protein kinase ERK5 was also inserted in the retroviral vector. Viral particles produced in 293T cells were used to infect HeLa cells in the presence or absence of OOS or VS. It was observed that VS had a minimal effect on the capacity of either lentivirus or retrovirus to infect HeLa cells. However, OOS significantly reduced the infection of HeLa cells with both of these viruses. The effect was dose‑dependent, reaching a maximum at a 1:100 dilution of OOS. These results suggested that, in addition to its well‑known antitumoral properties, OOS may also inhibit infection with viruses. This effect is relevant since patients receiving oncological therapies are more susceptible to viral infections, and nutritional supplements such as OOS may help in reducing the severity of these potential pathogenic infections.

View Figures

View References

1	McComb S, Thiriot A, Akache B, Krishnan L and Stark F: Introduction to the immune system. Methods Mol Biol. 2024:1–24. 2019.PubMed/NCBI View Article : Google Scholar
2	Parkin J and Cohen B: An overview of the immune system. Lancet. 357:1777–1789. 2001.PubMed/NCBI View Article : Google Scholar
3	Pandiella-Alonso A, Diaz-Rodriguez E and Sanz E: Antitumoral properties of the nutritional supplement ocoxin oral solution: A comprehensive review. Nutrients. 12(2661)2020.PubMed/NCBI View Article : Google Scholar
4	Gomez EV, Perez YM, Sanchez HV, Forment GR, Soler EA, Bertot LC, Garcia AY, del Rosario Abreu Vazquez M and Fabian LG: Antioxidant and immunomodulatory effects of Viusid in patients with chronic hepatitis C. World J Gastroenterol. 16:2638–2647. 2010.PubMed/NCBI View Article : Google Scholar
5	Vilar Gomez E, Sanchez Rodriguez Y, Torres Gonzalez A, Calzadilla Bertot L, Arus Soler E, Martinez Perez Y, Yasells Garcia A and Abreu Vazquez Mdel R: Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: A randomised and controlled trial. BMJ Open. 1(e000140)2011.PubMed/NCBI View Article : Google Scholar
6	Vilar Gomez E, Gra Oramas B, Soler E, Llanio Navarro R and Ruenes Domech C: Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Liver Int. 27:247–259. 2007.PubMed/NCBI View Article : Google Scholar
7	Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B, Arus Soler E, Llanio Navarro R, Calzadilla Bertot L, Yasells Garcia A and Del Rosario Abreu Vazquez M: Clinical trial: A nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 30:999–1009. 2009.PubMed/NCBI View Article : Google Scholar
8	Diaz-Rodriguez E, El-Mallah AM, Sanz E and Pandiella A: Antitumoral effect of Ocoxin in hepatocellular carcinoma. Oncol Lett. 14:1950–1958. 2017.PubMed/NCBI View Article : Google Scholar
9	Diaz-Rodriguez E, Hernandez-Garcia S, Sanz E and Pandiella A: Antitumoral effect of Ocoxin on acute myeloid leukemia. Oncotarget. 7:6231–6242. 2016.PubMed/NCBI View Article : Google Scholar
10	Diaz-Rodriguez E, Sanz E and Pandiella A: Antitumoral effect of Ocoxin, a natural compound-containing nutritional supplement, in small cell lung cancer. Int J Oncol. 53:113–123. 2018.PubMed/NCBI View Article : Google Scholar
11	Hernandez-Garcia S, Gonzalez V, Sanz E and Pandiella A: Effect of oncoxin oral solution in HER2-overexpressing breast cancer. Nutr Cancer. 67:1159–1169. 2015.PubMed/NCBI View Article : Google Scholar
12	Hernandez-SanMiguel E, Gargini R, Cejalvo T, Segura-Collar B, Núñez-Hervada P, Hortigüela R, Sepúlveda-Sánchez JM, Hernández-Laín A, Pérez-Núñez A, Sanz E and Sánchez-Gómez P: Ocoxin modulates cancer stem cells and M2 macrophage polarization in glioblastoma. Oxid Med Cell Longev. 2019(9719730)2019.PubMed/NCBI View Article : Google Scholar
13	Hernandez-Unzueta I, Benedicto A, Olaso E, Sanz E, Viera C, Arteta B and Márquez J: Ocoxin oral solution^® as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cancer to the liver. Oncol Lett. 13:4002–4012. 2017.PubMed/NCBI View Article : Google Scholar
14	Hernandez-Unzueta I, Benedicto A, Romayor I, Herrero A, Sanz E, Arteta B, Olaso E and Márquez J: Ocoxin oral solution exerts an antitumoral effect in pancreatic cancer and reduces the stromal-mediated chemoresistance. Pancreas. 48:555–567. 2019.PubMed/NCBI View Article : Google Scholar
15	Perez-Pena J, Diaz-Rodriguez E, Sanz E and Pandiella A: Central role of cell cycle regulation in the antitumoral action of ocoxin. Nutrients. 11(1068)2019.PubMed/NCBI View Article : Google Scholar
16	Rusu RA, Sirbu D, Curseu D, Năsui B, Sava M, Vesa ŞC, Bojan A, Lisencu C and Popa M: Chemotherapy-related infectious complications in patients with Hematologic malignancies. J Res Med Sci. 23(68)2018.PubMed/NCBI View Article : Google Scholar
17	Vento S and Cainelli F: Infections in patients with cancer undergoing chemotherapy: Aetiology, prevention, and treatment. Lancet Oncol. 4:595–604. 2003.PubMed/NCBI View Article : Google Scholar
18	Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, Zhang Z, You H, Wu M, Zheng Q, et al: Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak. Cancer Discov. 10:783–791. 2020.PubMed/NCBI View Article : Google Scholar
19	Fuentes-Antras J, Manzano A, Marquina G, Paz M, Aguado C, Granja M, Benítez J, Ortega J, Priego A, González C, et al: A snapshot of COVID-19 infection in patients with solid tumors. Int J Cancer: Dec 3, 2020 (Epub ahead of print). doi: 10.1002/ijc.33420.
20	Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, et al: A review of human carcinogens-Part B: Biological agents. Lancet Oncol. 10:321–322. 2009.PubMed/NCBI View Article : Google Scholar
21	Fernandez AF and Esteller M: Viral epigenomes in human tumorigenesis. Oncogene. 29:1405–1420. 2010.PubMed/NCBI View Article : Google Scholar
22	Diaz-Rodriguez E and Pandiella A: Modulation of cereblon levels by anti-myeloma agents. Leuk Lymphoma. 57:167–176. 2016.PubMed/NCBI View Article : Google Scholar
23	Diaz-Rodriguez E, Álvarez-Fernández S, Chen X, Paiva B, López-Pérez R, García-Hernández JL, San Miguel JF and Pandiella A: Deficient spindle assembly checkpoint in multiple myeloma. PLoS One. 6(e27583)2011.PubMed/NCBI View Article : Google Scholar
24	Al-Mahtab M, Akbar SM, Khan MS and Rahman S: Increased survival of patients with end-stage hepatocellular carcinoma due to intake of ONCOXIN(R), a dietary supplement. Indian J Cancer. 52:443–446. 2015.PubMed/NCBI View Article : Google Scholar
25	Gray Lovio OR, Abreu Daniel A, García Yánez LA, Rodríguez MO, González CV, Lence Anta JJ and Sanz E: Efficacy and safety of oncoxin-viusid, a nutritional supplement, in twenty patients with stage IIB-III of cutaneous melanoma: An open-label proof of concept study. J Cancer Sci Ther. 11:263–268. 2019.
26	Rivas IC, Silva JA, Alfonso G, Candanedo H, Cuervo Y, Mestre B, Mestre Cabello JR, Lence J, Lugoyo M and Sanz E: Oncoxin-viusid with radiotherapy and chemotherapy in patients with head and neck cancer: Results from a phase II, randomised, double-blind study. J Cancer Sci Ther. 10:317–327. 2018.
27	Fundora Ramos MI, Maden LB, Casanova FO, Cruz FH, Reyes CS, Gato AH, Lyncon IB, González EV, Morales KP, Lence JJ and Sanz E: Oncoxin-Viusid^® may improve quality of life and survival in patients with hormone-refractory prostate cancer undergoing onco-specific treatments. Mol Clin Oncol. 14(5)2021.PubMed/NCBI View Article : Google Scholar
28	Ruiz Lorente R, Hernández Durán D, García Viamontes J, Lence Anta J, Ortiz Reyes R and Sanz E: Efficacy of Oncoxin-viusid on the reduction of adverse reactions to chemotherapy and radiotherapy in patients diagnosed with cervical cancer and endometrial adenocarcinoma. J Cancer Ther. 11:276–295. 2020.
29	Uddin D, Islam MA, Mahmood I, Ghosh AK, Khatun RA and Kundu S: Findings of the 3-month supportive treatment with ocoxin solution beside the standard modalities of patients with different neoplastic diseases. TAJ. 22:172–175. 2009.
30	Kaidarova DR, Kopp MV, Pokrovsky VS, Dzhugashvili M, Akimzhanova ZM, Abdrakhmanov RZ, Babich EN, Bilan EV, Byakhov AV, Gurov SN, et al: Multicomponent nutritional supplement Oncoxin and its influence on quality of life and therapy toxicity in patients receiving adjuvant chemotherapy. Oncol Lett. 18:5644–5652. 2019.PubMed/NCBI View Article : Google Scholar
31	Ashraf S, Alam J, Sarkar JA, Khondaker FA, Farhana Y and Khan NA: An open-label randomized clinical study to compare the effects of a nutritional supplement versus vitamin E on fibroscan score in nonalcoholic steatohepatitis (NASH) patients. Univ J Public Health. 6:56–62. 2018.
32	Pascal R and Russu E: ‘Viusud’ as a immnunomodultaor drug for the treatment of immunological disturbances in psoriatic arthritis. Arta Medica. 4:38–42. 2006.
33	Valencia MH, Pacheco AC, Quijano TH, Girón AV and López CV: Clinical response to glycyrrhizinic acid in genital infection due to human papillomavirus and low-grade squamous intraepithelial lesion. Clin Pract. 1(e93)2011.PubMed/NCBI View Article : Google Scholar
34	de Martel C, Georges D, Bray F, Ferlay J and Clifford GM: Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. Lancet Glob Health. 8:e180–e190. 2020.PubMed/NCBI View Article : Google Scholar
35	Plummer M, de Martel C, Vignat J, Ferlay J, Bray F and Franceschi S: Global burden of cancers attributable to infections in 2012: A synthetic analysis. Lancet Glob Health. 4:e609–e616. 2016.PubMed/NCBI View Article : Google Scholar
36	Schelhaas M: Viruses and cancer: Molecular relations and perspectives. Biol Chem. 398:815–816. 2017.PubMed/NCBI View Article : Google Scholar
37	Dominguez Gomez J, Simon RD, Abreu Daniel A and Zelenkova H: Effectiveness of glycyrrhizinic Acid (glizigen) and an immunostimulant (viusid) to treat anogenital warts. ISRN Dermatol. 2012(863692)2012.PubMed/NCBI View Article : Google Scholar
38	Bae M and Kim H: Mini-review on the roles of vitamin C, vitamin D, and selenium in the immune system against COVID-19. Molecules. 25(5346)2020.PubMed/NCBI View Article : Google Scholar
39	Menegazzi M, Campagnari R, Bertoldi M, Crupi R, Di Paola R and Cuzzocrea S: Protective effect of epigallocatechin-3-gallate (EGCG) in diseases with uncontrolled immune activation: Could such a scenario be helpful to counteract COVID-19? Int J Mol Sci. 21(5171)2020.PubMed/NCBI View Article : Google Scholar
40	Mhatre S, Srivastava T, Naik S and Patravale V: Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID-19: A review. Phytomedicine. 85(153286)2021.PubMed/NCBI View Article : Google Scholar
41	Mrityunjaya M, Pavithra V, Neelam R, Janhavi P, Halami PM and Ravindra PV: Immune-boosting, antioxidant and anti-inflammatory food supplements targeting pathogenesis of COVID-19. Front Immunol. 11(570122)2020.PubMed/NCBI View Article : Google Scholar
42	Lammi C and Arnoldi A: Food-derived antioxidants and COVID-19. J Food Biochem. 45(e13557)2020.PubMed/NCBI View Article : Google Scholar
43	Benites W, Heras MV, Mero ML and Marquez D: Effectiveness of VIUSID^® and ASBRIP^® in hospitalized patients infected by SARS-CoV-2 and mild-to-moderate respiratory illness. An observational prospective study. Clin Infect Dis. (5)2021.
44	Petrov P, Mihaylov A, Shopove M, Boncheva M and Marquez D: Efficacy and safety of viusid and asbrip in hospitalized patients with mild and moderate COVID-19: A randomized controlled trial. Adv Infectious Dis. 11:171–184. 2021.